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Abstract
Background: The presence of comorbidity affects the care of cancer patients, many of whom are living with
multiple comorbidities. The prevalence of cancer comorbidity, beyond summary metrics, is not well known.
This study aims to estimate the prevalence of comorbid conditions among cancer patients in England, and
describe the association between cancer comorbidity and socio-economic position, using population-based
electronic health records.
Methods: We linked England cancer registry records of patients diagnosed with cancer of the colon, rectum,
lung or Hodgkin lymphoma between 2009 and 2013, with hospital admissions records. A comorbidity was
any one of fourteen specific conditions, diagnosed during hospital admission up to 6 years prior to cancer
diagnosis. We calculated the crude and age-sex adjusted prevalence of each condition, the frequency of
multiple comorbidity combinations, and used logistic regression and multinomial logistic regression to
estimate the adjusted odds of having each condition and the probability of having each condition as a single
or one of multiple comorbidities, respectively, by cancer type.
Results: Comorbidity was most prevalent in patients with lung cancer and least prevalent in Hodgkin
lymphoma patients. Up to two-thirds of patients within each of the four cancer patient cohorts we studied
had at least one comorbidity, and around half of the comorbid patients had multiple comorbidities. Our
study highlighted common comorbid conditions among the cancer patient cohorts. In all four cohorts, the
odds of having a comorbidity and the probability of multiple comorbidity were consistently highest in the
most deprived cancer patients.
Conclusions: Cancer healthcare guidelines may need to consider prominent comorbid conditions, particularly
to benefit the prognosis of the most deprived patients who carry the greater burden of comorbidity. Insight
into patterns of cancer comorbidity may inform further research into the influence of specific comorbidities
on socio-economic inequalities in receipt of cancer treatment and in short-term mortality.
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Background
Comorbidity refers to the existence of a long-term
health condition in the presence of a primary disease of
interest [1]. Having one or more comorbidities may in-
fluence the patient’s prognosis for a primary disease
such as cancer. Comorbidity may influence the timing of
cancer diagnosis, in either a positive or a negative way.
For example, the symptoms of comorbidity may drive a pa-
tient to seek medical care sooner, potentially leading to an
earlier diagnosis. Alternatively, cancer symptoms may be
mistakenly considered as symptoms of a pre-existing health
condition, and could delay diagnosis [2–4]. Following diag-
nosis, the presence of comorbidity may also influence tim-
ing, receipt, or outcome of treatment, with clear evidence
that those with comorbidity are less likely to receive curative
treatment than those without, despite increasing evidence
that many patients with comorbidity benefit from such
treatment [3]. Although the presence of multiple co-existent
health conditions is commonplace, the guidelines, funding
and structures of primary care may not support the care of
more patients with multiple conditions [5], and care in sec-
ondary and tertiary centres is typically highly siloed [3].
Methods used in the scientific literature to describe,
measure and quantify the status of comorbidity as an ex-
planatory factor in adverse disease outcomes are varied.
Many summarised metrics of comorbidity have been
proposed, providing an overall picture of a patient’s co-
morbidity status, some specific to a primary disease
while others are more general. For example, a widely
used metric of comorbidity in epidemiological studies is
the Charlson Comorbidity Index (CCI) [6], which
weights 19 long-term health conditions according to
their relative risk of one-year mortality, to produce an
overall index score.
In this study, we firstly aimed to examine the preva-
lence of comorbid conditions in cancer patients using
English population-based electronic health records of
patients diagnosed with cancer of the colon, rectum, or
lung or with Hodgkin lymphoma (HL). An association
between comorbidity (not specific to any primary disease
of interest) and socio-economic position has been widely
reported: the prevalence of certain specific comorbid
conditions [7–10] and general comorbidity prevalence
being higher in deprived groups of patients [11–13]. Our
second aim was to describe patterns of comorbidities
and multiple comorbidity in these cancer patient co-
horts, according to patient characteristics such as socio-
economic position (deprivation).
Methods
We defined a comorbid condition as one of the follow-
ing fourteen health conditions: myocardial infarction
(MI), congestive heart failure (CHF), peripheral vascular
disease (PVD), cerebrovascular disease (CVD), dementia,
chronic obstructive pulmonary disease (COPD), rheum-
atological conditions, liver disease, diabetes, hemiplegia
or paraplegia, renal disease, previous malignancy, obesity
or hypertension. The conditions, selected following a
systematic search of the data, included conditions of the
Charlson Comorbidity Index [6] and any highly preva-
lent conditions that may influence cancer management
alone or in combination with another condition.
Data
This study used England National Cancer Registry data
of 331,655 patients aged 15–90 years at diagnosis with
cancer of the colon, rectum, lung or Hodgkin’s lymph-
oma, between 2009 and 2013. Registry data provided in-
formation on patient sex, age at diagnosis, site of cancer,
date of cancer diagnosis and area of residence at time of
diagnosis, which was used to derive socio-economic pos-
ition, based on deprivation quintiles of the Income Do-
main of the Indices of Multiple Deprivation [14]. The
five-level, ordinal variable indicates the level of
deprivation from 1 (least deprived) to 5 (most deprived).
Areas of residence are defined at the Lower Super Out-
put Area level (mean population 1500).
Inpatient, outpatient and emergency hospital admis-
sions records (Hospital Episode Statistics, HES) [15]
were successfully linked with over 99% of the cancer
registry records, using common unique variables present
in both data sources. The International Statistical Classi-
fication of Diseases and Related Health Conditions tenth
edition (ICD-10) [16] codes captured within the diagnos-
tic fields of HES records provided information on health
conditions recorded during hospital admissions. We
used the ICD-10 code groupings of health conditions
proposed by Quan and colleagues for defining comor-
bidities using administrative data (see Additional file 1)
[17], and used an algorithm [18] to identify whether
these conditions had been recorded in the six-year
period prior to cancer diagnosis. In contrast to the ap-
proach of Maringe and colleagues [18], we included
diagnoses of conditions recorded up to 6 months prior
to cancer diagnosis. We anticipated that first-time diag-
noses of the conditions could occur in this period, and
wanted to obtain the most complete picture of patient
comorbidity. We used cancer registry data to identify
whether a patient had been diagnosed with an unrelated
malignancy up to 6 years before their diagnosis with the
cancer of interest.
Descriptive data analysis
We calculated the prevalence of a comorbid condition
within each of the four patient cohorts defined by cancer
site, firstly as a crude measure, calculating the percent-
age of patients who had a recorded diagnosis of the co-
morbidity in HES records, and secondly adjusting for
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age and sex to account for the older age demographic of
cancer patient populations. Weights for this adjustment
were obtained from 2011 UK census published popula-
tion estimates of persons living in England [19].
Statistical analysis
Logistic regression models were used to estimate the
odds ratio (OR) of having each comorbidity by cancer
site, adjusting for sex, age at cancer diagnosis and
deprivation group. The binary outcome variable indi-
cated the presence of the comorbidity. To account for a
non-linear association between increasing age and the
presence of comorbidity, age was modelled as a continu-
ous variable using a restricted cubic spline with one knot
fixed at 70 years in analyses conducted for cancers of the
colon, rectum and lung and at 45 years for HL (the knot
position was chosen as to be close to the mean age of
the patients in each of these cancer cohorts). To reduce
the risk of unstable models, we ensured there were at
least ten or more occurrences of a comorbidity within
the specific cancer patient cohort for every parameter of
the model (events per variable, EPV) [20].
Multinomial logistic regression was used to estimate
the probability of having a given comorbidity, either in
isolation, or as one of multiple comorbidities, according
to cancer site. The three-category outcome variable indi-
cated whether the patient did not have the given comor-
bidity, only had this comorbidity, or had this
comorbidity with other comorbidities. Models were ad-
justed for age, sex and deprivation, and were run for
each cancer site and comorbidity combination with at
least ten EPV.
All data analyses were conducted in STATA v.15.1
[21].
Results
Patient characteristics
The characteristics of patients diagnosed with cancer of
the colon (N = 102,216), rectum (N = 56,342), lung (N =
165,677) or with HL (N = 7420) between 2009 and 2013,
stratified by comorbidity status, are shown in Table 1.
The majority of patients in each cohort were male: ap-
proximately 55% of colon, lung and HL patients and
63% of rectal cancer patients. At least 80% of colon, rec-
tum and lung cancer patients were in the two oldest age
group categories, while 50% of the HL patients were
within the two youngest age groups. There was an even
distribution of patients among each of the deprivation
groups, except among lung cancer patients, where the
percentage of patients in each group increased with
deprivation level.
Comorbidity was over twice as prevalent in lung can-
cer patients than in patients with HL: 67% of lung can-
cer patients had one or more comorbidities versus
almost 30% of HL patients. Similar patterns in comor-
bidity prevalence were seen in males and females. The
prevalence of either single or multiple comorbidity rose
with increasing age. Single comorbidity was more com-
mon than multiple comorbidity in the younger age
groups, whereas in the older patients the opposite was
observed. For example, approximately 29.2% of lung can-
cer patients aged 15–29 years had one comorbidity and
3.4% had multiple comorbidities, while in lung cancer
patients aged 75–90 years the percentage of patients
with one comorbidity or with multiple comorbidities
were 26.9 and 49.9%, respectively.
The prevalence of multiple comorbidity increased with
deprivation level in colon, rectum and lung cancer pa-
tients, but there was no pattern with deprivation in HL
patients or in the prevalence of one comorbidity. For ex-
ample, from 24.7 to 25.7% of rectal cancer patients had
one comorbidity, while 17.7 to 27.6% of patients had
multiple comorbidities.
Crude and adjusted prevalence of comorbidities at the
time of cancer diagnosis
Across all cancer patient cohorts, hypertension, COPD,
diabetes, CVD, CHF and PVD were among the most
commonly recorded comorbid conditions. Adjusting for
age and sex strongly impacted the prevalence of some
comorbid conditions in colon, rectum and lung cancer
patients (Fig. 1). The three most prevalent comorbidities
in all four cancer patient cohorts were hypertension,
COPD and diabetes. The adjusted prevalence of hyper-
tension and of diabetes was similar among patients in
each of the four cohorts (approximately 15–20% of pa-
tients had hypertension while approximately 5% of pa-
tients had diabetes). However, the adjusted prevalence of
COPD was markedly higher in patients with lung cancer:
approximately 25% of lung cancer patients had COPD
versus 10% of patients in the other patient cohorts. Simi-
larly, in comparison between the four cohorts, the preva-
lence of several other conditions (CVD, CHF, PVD or
previous malignancy) was highest among the lung cancer
patients.
Combinations of multiple comorbidity
The relative frequency (%) in which five of the most
common conditions (COPD, diabetes, CVD, CHF and
PVD) are present either as a single comorbidity or in
combination with ten other common comorbid condi-
tions is shown in Fig. 2. For a given cancer (identified by
colour), the denominator is the number of patients with
the comorbid condition, as represented on the y-axis,
and the numerator is the number of those patients who
had the condition as a single comorbidity or who had
another condition, as depicted by the x-axis. Patients
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with two or more of the x-axis conditions are repre-
sented in the numerator for each condition.
Approximately one third of colorectal and lung cancer
patients with COPD, and over half of HL patients with
COPD, had this condition as a single comorbidity. By
comparison, under one fifth of patients with diabetes,
CVD, CHF and PVD had these conditions as a single co-
morbidity. CHF was the condition least frequently ob-
served as a single comorbidity across all four cancer
sites (89% or more of patients with CHF had additional
comorbidities).
Hypertension was the condition most commonly
present with each of comorbidities for which cross
tabulations were investigated. In each of the cancer
cohorts, approximately three-quarters of patients with
CHF, and a similar proportion with CVD, also had
hypertension. COPD was most commonly seen in
combination with diabetes, CVD, CHF or PVD in
lung cancer patients: while over 50% of lung cancer
patients with CHF also had COPD, around one third
of patients with HL, colon or rectal cancers with
CHF also had COPD.
Multivariate analysis
The odds ratios derived from logistic regression of each
comorbid condition being present at the time of cancer
diagnosis, by cancer site, for females relative to males,
age (relative to age 70 in colon, rectal and lung cancer
patients, and relative to age 45 in HL patients) and in-
creasing deprivation, adjusted for the other listed vari-
ables, are shown in Table 2. Analyses conducted for
patients with HL were restricted to the comorbidities of
diabetes, hypertension and COPD, as the prevalence
counts of the other conditions did not adhere to the
minimum of ten EPV required for the analyses.
Female patients with colon, rectal or lung cancer had
up to 29% increased adjusted odds of having dementia
(rectal cancer: OR 1.29; 95%CI 1.13, 1.48), up to 34% in-
creased adjusted odds of having a previous malignancy
(rectal cancer: OR 1.34; 1.23, 1.47) and approximately
twice the adjusted odds of having rheumatological con-
ditions (colon cancer: OR 2.16; 1.98, 2.36) compared to
male patients. Conversely, compared with male patients
in their respective cohort, females had significantly re-
duced adjusted odds of having diabetes, hemiplegia or
0
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Fig. 1 Crude and adjusted prevalence (%) of fourteen comorbidities among cancer patients in England, by cancer
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paraplegia, CVD, renal disease, MI, CHF or PVD. Across
all four cancer cohorts, female patients had up to 38%
reduced odds of having diabetes (HL: OR 0.62; 95%CI
0.50, 0.77).
The adjusted odds of dementia, CVD, hypertension,
renal disease, MI and CHF being present at diagnosis
consistently increased with age. For example, with 70-
year old patients as the reference, colon cancer patients
aged 45 had 87% reduced adjusted odds of CVD (OR
0.13; 0.13, 0.13) and 88% reduced adjusted odds of CHF
(OR 0.12; 0.12, 0.12), while 90-year old patients had over
three times the adjusted odds of CVD (OR 3.27; 2.69,
3.99) and over four times the adjusted odds of CHF (OR
4.72; 3.63, 6.13). There was no trend with age in colon,
rectal or lung cancer patients for liver disease, having
had a previous malignancy, diabetes or obesity. In lung
cancer patients, no trend was observed with age for hav-
ing COPD.
For at least eleven of the fourteen conditions, the ad-
justed odds of having the comorbid condition increased
with the level of deprivation in colon, rectal or lung can-
cer patients. Obesity, dementia, hemiplegia, CVD, hyper-
tension, renal disease, MI, COPD, CHF and PVD were
associated with deprivation level in all three cancer co-
horts. For example, the most deprived groups of lung
cancer and colon cancer patients had approximately
twice the adjusted odds of having COPD compared with
the least deprived groups (OR 1.96; 1.89, 2.03 and OR
2.01; 1.89, 2.12 in the most deprived patients with lung
or colon cancer, respectively). No trend with deprivation
was seen with rheumatological conditions or with having
a previous malignancy.
Probability of having single or multiple comorbidity at
the time of cancer diagnosis
The graphs depicted in Fig. 3 show the adjusted prob-
ability of patients having one of the nine most common
comorbid conditions recorded (hypertension, COPD,
diabetes, CHF, CVD, PVD, MI, obesity or rheumato-
logical conditions) at the time of colon cancer diagnosis,
either as a single comorbidity, or as one of multiple co-
morbidities, according to age at cancer diagnosis and
deprivation group (the least and most deprived groups),
as derived from multinomial logistic regression.
With the exception of COPD, there was little differ-
ence between the most and least deprived groups in the
probability of having each of the conditions as a single
comorbidity. Among those patients with COPD as a
single comorbidity, the difference in probability between
Fig. 2 Relative frequency (%) of five common conditions as a single comorbidity or with another comorbidity, by cancer
Fowler et al. BMC Cancer            (2020) 20:2 Page 6 of 15
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the most and least deprived groups decreased with age.
The most deprived patients had a higher probability of
having each of the conditions as one of multiple comor-
bidities compared with the least deprived group, with
one exception (rheumatological conditions). Generally,
the difference in probability between the two deprivation
groups was greatest in older age: it peaked at approxi-
mately 80 years for hypertension, COPD, diabetes, PVD
and obesity, while in patients with CHF, CVD, and MI
the difference continued to increase with age. Having
rheumatological conditions was not associated with in-
creasing age or deprivation level.
Similar patterns in the probability of having a comor-
bid condition according to deprivation group were ob-
served for patients with rectal or lung cancers
(Additional files 2 and 3).
Discussion
Our study is, to our knowledge, the first large-scale,
population-based study describing comorbidity preva-
lence in cancer patient populations. Up to two-thirds of
patients had at least one long-term health condition at
the time of their cancer diagnosis, and around half of
these comorbid cancer patients had multiple long-
term conditions. There was evidence that many of the
comorbid conditions we investigated were associated
with socio-economic deprivation, and the most de-
prived groups of patients had a higher probability of
having multiple comorbidities compared with the less
deprived groups.
The choice of cancer sites we studied was based on
aetiology of the cancer: three of the cancer sites (colon,
rectum and lung) were associated with environmental
risk factors including tobacco smoking [22, 23], alcohol
use and diet [24, 25]. Furthermore, tobacco smoking is
associated with certain conditions, such as COPD [26–28]
and Type 2 diabetes [29, 30], and is also associated with
socioeconomic position [31]. HL is linked to infection ra-
ther than environmental factors [22].
Hypertension, COPD and diabetes were the three most
prevalent comorbidities in all four cancer patient co-
horts, with a higher prevalence in the most deprived pa-
tients. The odds of having COPD from being in the
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Fig. 3 Probability (%) of condition present as single or multiple comorbidity, by deprivation group (colon cancer)
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most deprived group of lung cancer patients (compared
with being in the least deprived group – the ‘deprivation
gap’) was 10% more than the deprivation gap in the ad-
justed odds of having COPD in the Hodgkin lymphoma pa-
tients. This may be reflective of the role of smoking in the
aetiology of both lung cancer and COPD, and the higher
prevalence of smoking in the more deprived population.
The association between smoking status and deprivation is
not quantifiable in the cancer patient cohorts as we did not
have information on smoking prevalence.
Similar work using administrative data to describe co-
morbidity in cancer populations has been undertaken in
New Zealand [32] and in Spain [33]. In the study of pa-
tients diagnosed with colon, rectal, breast, ovarian, uter-
ine, stomach, liver, renal or bladder cancers in New
Zealand (N = 14,096), commonly diagnosed comorbidi-
ties among colon and rectal cancer patients were hyper-
tension, cardiac conditions and diabetes. In the Spanish
cohort of colorectal cancer patients from the cancer
registries of Girona and Granada (N = 1061), diabetes,
COPD and CHF were the most common comorbidities.
Comparing our study with the study in New Zealand,
there were similarities among colon cancer patients in
the age-sex adjusted prevalence of hypertension, while
diabetes prevalence was higher in New Zealand. The ad-
justed prevalence of hypertension was 16.6%, uncompli-
cated diabetes was 5.9% and diabetes with complications
was 5.0% among patients in New Zealand, while in our
study the adjusted prevalence of hypertension was 17.4%
and diabetes (with and without complications) was 5.7%.
This supports our earlier assumption that less severe
diabetes may be underreported in hospital admissions
records. Given the ‘gatekeeper’ structure and functioning
of the healthcare system in the UK [34] and the focus on
managing diabetes within primary care [35], cases of dia-
betes recorded in hospital admissions are possibly those
that are not controlled within available primary care re-
sources [36] or present with complications. The Spanish
study reported the crude prevalence of conditions
among colorectal cancer patients, which were generally
higher than the crude prevalence of conditions observed
in our study. Diabetes was prevalent in 23.6% of colorec-
tal cancer patients in this study, while in our study the
crude prevalence of diabetes was 11.4% or 9.4% among
colon or rectal cancer patients, respectively. Nonetheless,
there was consistency between our study and both of
these other studies in terms of common comorbid con-
ditions among the patient cohorts.
In our study, approximately 13% of the HL cohort,
over 21% of the colorectal cancer cohorts and over 39%
of the lung cancer cohort had multiple comorbidities,
while from 17 to 28% of patients in each cohort had a
single comorbidity at the time of their cancer diagnosis.
These findings are important given the impact
comorbidity may have on cancer care, particularly where
care is provided within the constraints of healthcare
guidelines that are not designed for the simultaneous
management of two or more chronic conditions or mor-
bidities (i.e. “multimorbidity”). Scientific studies indicate
that multimorbidity is regularly observed in the popula-
tion [37–39] and poses a challenge to health care sys-
tems, particularly those geared towards single disease
management [5, 40, 41]. Clinical guidelines in the United
Kingdom are not accommodating to the cumulative im-
pact of treatment recommendations on those with mul-
tiple morbidities, and do not facilitate a comparison of
potential benefits or risks [42]. Patients with multiple
chronic conditions have higher rates of healthcare con-
sultations than those without [38, 43, 44]. Managing and
treating comorbid conditions places an additional eco-
nomic burden on healthcare systems. In one study of the
costs per capita of several comorbid conditions, renal
disease was identified as one of the most costly condi-
tions to manage among cancer patients (approximately
174% of the costs of the cancer), while the cost of dia-
betes or heart disease was substantially lower (approxi-
mately 20% or 6% of cancer costs, respectively) [45]. The
increase in costs also depends on the number and com-
bination of comorbid conditions: among the cancer pa-
tients with diabetes in our study, between 10 and 15% of
these patients also had renal disease.
In cancer patients, the presence of comorbidity can be
influential on cancer management and therapeutic op-
tions. Patients with comorbidity may be less likely than
those without comorbidity to receive curative treatment
[3]. Treatment decisions made by clinicians may be
weighted by the type and severity of comorbidity, for ex-
ample, CHF has been reported to influence receipt of
surgery for non-small cell lung cancer [46], receipt of
adjuvant chemotherapy for colon cancer [47] and receipt
of any treatment for prostate cancer [48]. The presence
of COPD influenced receipt of surgical treatment in
non-small cell lung cancer patients [46] and adjuvant
therapy in colon cancer patients [47]. However, there is
also evidence that comorbid patients who receive treat-
ment have better prognosis for survival than those who
do not receive treatment, as shown with the receipt of
adjuvant therapy for colon cancer [47, 49]. Moreover,
older cancer patients and patients with comorbidity have
historically been under-represented in cancer clinical tri-
als. This limits the applicability of cancer clinical trial
results to a younger and healthier cohort of patients
than clinicians are actually treating, meaning that while
there is evidence suggesting that patients with comor-
bidity as a group are not receiving optimal cancer treat-
ment, specific information required for clinical decision-
making is often lacking [50]. We found a non-negligible
increase in the prevalence of comorbidities when we
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included diagnoses in the six-months prior to cancer
diagnoses. While some of these conditions may have
arisen in these months because of the cancer, their pres-
ence will be as relevant when considering treatment, ir-
respective of the timing of their diagnosis.
Our study showed socio-economic position to be an
important factor associated with having one or more co-
morbid conditions at the time of cancer diagnosis, with
comorbidity prevalence increasing with deprivation. It is
possible that mechanisms within clinical guidelines and
decision-making that lead to non-treatment of cancer
patients with comorbidity disproportionately impact the
more deprived patients. An existence of socio-economic
inequalities in receipt of treatment has been identified
[51, 52]. Reviewing the treatment process of cancer pa-
tients with comorbidity may therefore have a beneficial
effect in reducing the socioeconomic inequalities in re-
ceipt of cancer treatment. Moreover, because cancer
data contains mainly cancer-related outcomes, how the
cancer and related treatments impact patient comorbid-
ity and prognosis is not well known [3]. Having the re-
sources and guidelines within which to manage patient
comorbid conditions robustly during cancer treatment is
one strategy for mitigating the risk of adverse patient
outcomes occurring from comorbid disease. In England,
socio-economic inequalities in cancer survival have nar-
rowed little, despite the implementation of government
strategies that intended to reduce these inequalities [53].
Focusing on the management of comorbidity in cancer
patients could be one potential pathway to addressing
socio-economic inequalities in cancer outcomes.
There are a variety of metrics of comorbidity in the
scientific literature that are used to study the relation-
ship between comorbidity on cancer outcomes, although
no consensus has been reached on a gold standard
measure of comorbidity within the context of cancer
[54]. Many of the approaches provide a summary meas-
ure of the patient’s comorbid conditions and the severity
of these conditions. However, the prognostic impact of
comorbidity can depend on the type and stage of the
cancer [55]. In addition, the presence of comorbidity -
particularly certain comorbid conditions - adds com-
plexity to the provision of treatment for cancer. When
investigating the relationship between comorbidity and
cancer outcomes, a more granular approach investigat-
ing specific comorbid conditions in turn, rather than
using a summary measure of comorbidity, could be
more appropriate and insightful.
We acknowledge potential limitations in this study.
We capture comorbidity information based on diag-
noses of health conditions recorded during hospital
admission(s) prior to cancer diagnosis, and are there-
fore reliant on patients requiring hospital-based med-
ical attention for their health condition(s) in order to
obtain this information. The potential for measure-
ment error from the information recorded in the
diagnostic fields of hospital admissions records should
also be acknowledged. However, we assume that the
more severe conditions are likely to be captured
within the diagnostic fields. Underreporting may
occur in less severe conditions, such as obesity, that
are unlikely to be the primary reason for the hospital
admission, and may occur more frequently with eld-
erly patients or patients with more severe comorbidi-
ties, due to competing demands. Conditions such as
less severe type II diabetes are possibly underreported.
Further work comparing the prevalence of the condi-
tions we studied in the cancer cohorts with the
prevalence of these conditions in the general popula-
tion in England, as reported in government publica-
tions and scientific literature, would be useful step in
validating our results.
Our study of over 300,000 patients is one of the largest
population-based studies of comorbidity prevalence
among cancer patients, and one of the first such studies
of patients in England. Using data from well-established
sources, we were able to describe the prevalence of four-
teen chronic health conditions among these cancer pa-
tients, and highlight an association between socio-
economic position and prevalence of most of these
conditions.
Conclusion
This study underlines that many comorbid cancer pa-
tients are living with multiple comorbidities, and that
the most deprived patients carry the greater burden of
comorbidity. Healthcare guidelines may not always en-
compass the simultaneous management of multiple
chronic conditions, but guidelines for the management
of cancer may need to consider some prominent comor-
bid conditions. Insight into patterns of cancer comorbid-
ity informs further research into the influence of
comorbidity - particularly the influence of specific co-
morbid conditions - on outcomes following cancer diag-
nosis, including socio-economic inequalities in receipt of
treatment and short-term mortality.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1. Definition of the fourteen conditions, according to
ICD-10 code classification. Table of the fourteen conditions and the ICD-
10 code groupings used to define them.
Additional file 2. Probability (%) of condition present as single or multiple
comorbidity, by deprivation group (lung cancer). Additional results in
complement to those presented in Fig. 3: graphs representing the probability
of having any of nine comorbid conditions in lung cancer patients.
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Additional file 3. Probability (%) of condition present as single or
multiple comorbidity, by deprivation group (rectal cancer). Additional
results in complement to those presented in Fig. 3: graphs representing
the probability of having any of nine comorbid conditions in rectal
cancer patients.
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